After the opening of Hong Kong stocks today, B-class pharmaceutical stocks collectively fell. Some analysts pointed out that B-class pharmaceutical stocks in Hong Kong have the significance of "venture capital (risk investment) scientific progress", and there is great uncertainty in the future development of the company. When the market's risk preference declines, such stocks may be sold off, which may be one of the reasons for the collective decline of B-class pharmaceutical stocks in Hong Kong. In addition, Jun Shengtai Pharmaceutical has just been listed for 6 months, and the first stage of unlocking has also increased the selling pressure to a certain extent. It is worth noting that at the end of the day, the Hong Kong stock market suddenly surged and recovered the intraday decline. As of the close, the Hang Seng Index was unchanged, and it fell more than 1.3% at one point during the session; the Hang Seng China Enterprises Index rose 0.02%; the Hang Seng Tech Index fell 0.65%, and it fell more than 2% at one point during the session. At the current point in time, most institutions hold an optimistic view of the future market of Hong Kong stocks. China International Capital Corporation believes that further upward momentum in the Hong Kong stock market may require new catalysts to promote it, and it is expected that the Hang Seng Index will receive some support near 18,000 points; China Galaxy Securities has also expressed a positive view of the Hong Kong stock market. (Securities Times)